O. Jiménez-Zarazúa M.D., M.Sc. , M. Gil-Veloz M.D., Ph.D. , L.N. Vélez-Ramírez M.D. , E.E. Lozada Hernández M.D., Ph.D. , J.D. Mondragón M.D., Ph.D.
{"title":"评估重症和危重型COVID-19肺炎患者心外膜脂肪组织作为院内死亡率的预测因子","authors":"O. Jiménez-Zarazúa M.D., M.Sc. , M. Gil-Veloz M.D., Ph.D. , L.N. Vélez-Ramírez M.D. , E.E. Lozada Hernández M.D., Ph.D. , J.D. Mondragón M.D., Ph.D.","doi":"10.1016/j.rmed.2025.108085","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Given the impact of cardiovascular conditions on COVID-19 outcomes, there is increasing interest in assessing risk factors like epicardial adipose tissue (EAT). EAT contributes to metabolic syndrome, which worsens cardiovascular health through inflammation and insulin resistance, and triples mortality risk in COVID-19 patients. This study examined the relationship between EAT volume (EATV) and clinical outcomes in severe and critical SARS-CoV-2 pneumonia, hypothesizing that higher EATV would correlate with increased severity and mortality.</div></div><div><h3>Methods</h3><div>This multicenter retrospective cohort study of 750 COVID-19 patients with severe or critical pneumonia explored the relationships between EATV, the pulmonary severity index (PSI), the Kirby index, and 30-day in-hospital mortality. Outcomes included Sequential Organ Failure Assessment, Acute Physiology and Chronic Health Evaluation IV, Charlson comorbidity index, Kirby index, PSI, and 30-day in-hospital mortality. This retrospective cohort study evaluates EATV as a prognostic factor for COVID-19 mortality.</div></div><div><h3>Results</h3><div>EATV was significantly higher in patients with critical pneumonia and was also associated with increased mortality. EATV was the most robust predictor of in-hospital mortality, with a cut-off of 117 cm<sup>3</sup> indicating a higher risk.</div></div><div><h3>Discussion</h3><div>Epicardial adipose tissue volume was linked to increased mortality in patients with severe and critical pneumonia, especially in the third tertile. It was also associated with higher pulmonary severity indices and 30-day in-hospital mortality. Clinicians should consider EATV alongside inflammatory biomarkers to improve patient stratification and potentially enhance outcomes through earlier intervention.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"241 ","pages":"Article 108085"},"PeriodicalIF":3.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of epicardial adipose tissue in patients with severe and critical COVID-19 pneumonia as a predictor of in-hospital mortality\",\"authors\":\"O. Jiménez-Zarazúa M.D., M.Sc. , M. Gil-Veloz M.D., Ph.D. , L.N. Vélez-Ramírez M.D. , E.E. Lozada Hernández M.D., Ph.D. , J.D. Mondragón M.D., Ph.D.\",\"doi\":\"10.1016/j.rmed.2025.108085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Given the impact of cardiovascular conditions on COVID-19 outcomes, there is increasing interest in assessing risk factors like epicardial adipose tissue (EAT). EAT contributes to metabolic syndrome, which worsens cardiovascular health through inflammation and insulin resistance, and triples mortality risk in COVID-19 patients. This study examined the relationship between EAT volume (EATV) and clinical outcomes in severe and critical SARS-CoV-2 pneumonia, hypothesizing that higher EATV would correlate with increased severity and mortality.</div></div><div><h3>Methods</h3><div>This multicenter retrospective cohort study of 750 COVID-19 patients with severe or critical pneumonia explored the relationships between EATV, the pulmonary severity index (PSI), the Kirby index, and 30-day in-hospital mortality. Outcomes included Sequential Organ Failure Assessment, Acute Physiology and Chronic Health Evaluation IV, Charlson comorbidity index, Kirby index, PSI, and 30-day in-hospital mortality. This retrospective cohort study evaluates EATV as a prognostic factor for COVID-19 mortality.</div></div><div><h3>Results</h3><div>EATV was significantly higher in patients with critical pneumonia and was also associated with increased mortality. EATV was the most robust predictor of in-hospital mortality, with a cut-off of 117 cm<sup>3</sup> indicating a higher risk.</div></div><div><h3>Discussion</h3><div>Epicardial adipose tissue volume was linked to increased mortality in patients with severe and critical pneumonia, especially in the third tertile. It was also associated with higher pulmonary severity indices and 30-day in-hospital mortality. Clinicians should consider EATV alongside inflammatory biomarkers to improve patient stratification and potentially enhance outcomes through earlier intervention.</div></div>\",\"PeriodicalId\":21057,\"journal\":{\"name\":\"Respiratory medicine\",\"volume\":\"241 \",\"pages\":\"Article 108085\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0954611125001477\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611125001477","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Assessment of epicardial adipose tissue in patients with severe and critical COVID-19 pneumonia as a predictor of in-hospital mortality
Introduction
Given the impact of cardiovascular conditions on COVID-19 outcomes, there is increasing interest in assessing risk factors like epicardial adipose tissue (EAT). EAT contributes to metabolic syndrome, which worsens cardiovascular health through inflammation and insulin resistance, and triples mortality risk in COVID-19 patients. This study examined the relationship between EAT volume (EATV) and clinical outcomes in severe and critical SARS-CoV-2 pneumonia, hypothesizing that higher EATV would correlate with increased severity and mortality.
Methods
This multicenter retrospective cohort study of 750 COVID-19 patients with severe or critical pneumonia explored the relationships between EATV, the pulmonary severity index (PSI), the Kirby index, and 30-day in-hospital mortality. Outcomes included Sequential Organ Failure Assessment, Acute Physiology and Chronic Health Evaluation IV, Charlson comorbidity index, Kirby index, PSI, and 30-day in-hospital mortality. This retrospective cohort study evaluates EATV as a prognostic factor for COVID-19 mortality.
Results
EATV was significantly higher in patients with critical pneumonia and was also associated with increased mortality. EATV was the most robust predictor of in-hospital mortality, with a cut-off of 117 cm3 indicating a higher risk.
Discussion
Epicardial adipose tissue volume was linked to increased mortality in patients with severe and critical pneumonia, especially in the third tertile. It was also associated with higher pulmonary severity indices and 30-day in-hospital mortality. Clinicians should consider EATV alongside inflammatory biomarkers to improve patient stratification and potentially enhance outcomes through earlier intervention.
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.